Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
Dual checkpoint blockade of PD-L1 and cytotoxic T-lymphocyte-associated antigen-4 combined with metronomic oral vinorelbine demonstrated meaningful and durable clinical activity in patients with previously treated advanced cervical cancer. Toxicity was significant but manageable.
Authors
- F. Legrand
- Anthony Gonçalvès (ORCID: https://orcid.org/0000-0001-7570-7439)
- Renaud Sabatier (ORCID: https://orcid.org/0000-0002-5821-682X)
- Emmanuelle Charafe‐Jauffret (ORCID: https://orcid.org/0000-0002-0286-1299)
- Claire Cropet (ORCID: https://orcid.org/0000-0001-9412-5952)
- Jean‐Sébastien Frenel (ORCID: https://orcid.org/0000-0002-5273-0561)
- Alice Hervieu
- Elodie Coquan (ORCID: https://orcid.org/0000-0002-9497-0424)
- Pernelle Lavaud (ORCID: https://orcid.org/0000-0002-1286-5955)
- Olivia Le Saux (ORCID: https://orcid.org/0000-0002-7815-323X)
- Laurent Mathiot (ORCID: https://orcid.org/0000-0001-8601-1226)
- Marta Jimenez (ORCID: https://orcid.org/0000-0002-4233-8478)
- Thibault De La Motte Rouge (ORCID: https://orcid.org/0000-0002-0088-6003)
- Édith Borcoman (ORCID: https://orcid.org/0000-0002-5393-5657)
- Esma Saâda-Bouzid
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut Gustave Roussy (FR)
- Centre Georges François Leclerc (FR)
- Centre Léon Bérard (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Centre Eugène Marquis (FR)
- Centre François Baclesse (FR)
- UniCancer Group (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Institut Paoli-Calmettes (FR)
- Centre Antoine Lacassagne (FR)
- Institut Curie (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/jitc-2024-010708
- Citations
- 4
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.23
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Clovis Oncology
- Mylan
- Seagen
- Eisai
- Ligue Contre le Cancer
- Astellas Pharma
- Institut National Du Cancer
- Servier
- AstraZeneca France
- Ipsen
- Genentech
- Fondation Pierre Fabre
- Daiichi Sankyo Europe